Norman Schwartz - Bio Rad Chairman
| BIO Stock | USD 280.13 0.40 0.14% |
Chairman
Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Schwartz was our President and Chief Executive Officer since 2003 and our Chairman of the Board since 2012. He was our Vice President from 1989 to 2002, our Group Manager, Life Science, from 1997 to 2002 and our Group Manager, Clinical Diagnostics, from 1993 to 1997. We believe Mr. Schwartzs financial and business expertise gained through over 42 years of service with our Company, including as our President and Chief Executive Officer for over 16 years, give him the qualifications and skills to serve as a director. since 2012.
| Age | 74 |
| Tenure | 12 years |
| Address | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 |
| Phone | 510 724 7000 |
| Web | https://www.bio-rad.com |
Bio Rad Management Efficiency
The company has Return on Asset of 0.0177 % which means that on every $100 spent on assets, it made $0.0177 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0694) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.03. At this time, Bio Rad's Total Assets are very stable compared to the past year. As of the 23rd of April 2024, Non Current Assets Total is likely to grow to about 9.7 B, though Non Currrent Assets Other are likely to grow to (1.4 T).Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Michael Hill | Shattuck LabsInc | 38 | |
| Dr DPHIL | Kymera Therapeutics | 50 | |
| JeanPierre Sommadossi | Kezar Life Sciences | 62 | |
Management Performance
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0177 |
Bio Rad Laboratories Leadership Team
Elected by the shareholders, the Bio Rad's board of directors comprises two types of representatives: Bio Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Rad's management team and ensure that shareholders' interests are well served. Bio Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Stark, Principal Accounting Officer, Vice President Controller | ||
| Ajit Ramalingam, Senior Vice President Chief Accounting Officer | ||
| Shannon Hall, Executive Vice President and Presidentident, Life Science Group | ||
| Jeffrey Edwards, Independent Director | ||
| Lee Boyd, Senior Pacific | ||
| Andrew Last, Chief Operating Officer, Executive Vice President | ||
| Yong Chung, Vice Relations | ||
| Tania DeVilliers, Corporate Director | ||
| Arnold Pinkston, Independent Director | ||
| Christine Tsingos, CFO and Executive VP | ||
| Timothy Ernst, Executive Vice President General Counsel and Secretary | ||
| Ronald Hutton, Vice President Treasurer | ||
| Joel McComb, Director | ||
| Jim Barry, Senior Manufacturing | ||
| Alice Schwartz, Director | ||
| Gregory Hinckley, Lead Independent Director | ||
| Michael Crowley, Executive Vice President - Global Commercial Operations | ||
| Simon May, Executive Vice President and Presidentident - Life Science Group | ||
| Melinda Litherland, Independent Director | ||
| John Hertia, Executive Vice President, President, Clinical Diagnostics Group | ||
| John Goetz, COO and Executive VP | ||
| Louis Drapeau, Independent Director | ||
| Shawn Soderberg, Executive Vice President General Counsel, Secretary | ||
| Annette Tumolo, Executive Vice President and Presidentident, Life Science Group | ||
| Dara Wright, Executive Vice President and President of the Clinical Diagnostics Group | ||
| Norman Schwartz, Chairman of the Board, President, Chief Executive Officer | ||
| Ilan Daskal, Chief Financial Officer, Executive Vice President | ||
| Matthew Werner, Senior Officer | ||
| Colleen Corey, Executive Resources | ||
| Deborah Neff, Independent Director | ||
| Giovanni Magni, Executive Vice President, Chief Strategy Officer | ||
| Robert Malchione, Independent Director |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0177 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 7.78 B | ||||
| Shares Outstanding | 23.42 M | ||||
| Shares Owned By Insiders | 15.23 % | ||||
| Shares Owned By Institutions | 81.68 % | ||||
| Number Of Shares Shorted | 564.75 K | ||||
| Price To Earning | 2.90 X |
Bio Rad Investors Sentiment
The influence of Bio Rad's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bio. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bio Rad's public news can be used to forecast risks associated with an investment in Bio. The trend in average sentiment can be used to explain how an investor holding Bio can time the market purely based on public headlines and social activities around Bio Rad Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bio Rad's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bio Rad's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bio Rad's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bio Rad.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bio Rad in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bio Rad's short interest history, or implied volatility extrapolated from Bio Rad options trading.
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
| 0.63 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.64 | CRL | Charles River Labora Financial Report 9th of May 2024 | PairCorr |
Moving against Bio Stock
| 0.71 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Bio Stock analysis
When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.56) | Earnings Share (21.82) | Revenue Per Share 91.453 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0177 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.